Background. Detection of atypical squamous cells of undetermined significance (ASCUS) is a cervical cytologic finding that is suggestive but not definitive of squamous intraepithelial lesions (SILs).
Both the etiology and outcome of atypical squamous cells of undetermined significance (ASCUS) detected by cervical cytologic testing are uncertain, as the name implies. Although it is recommended that laboratories avoid this diagnosis when a more precise diagnosis can be given [1] , the inflammatory and predysplastic changes that lead to a diagnosis of ASCUS are typically reported in 5%-10% of Papanicolaou (Pap) tests [2] [3] [4] . For some women, ASCUS may be an indication of coexisting dysplasia. Moreover, a diagnosis of ASCUS may be the result of early cytologic findings in women eventually diagnosed with severe dysplasia, with more than one-third of cases of biopsy-proven cervical intraepithelial neoplasia being associated at the preceding Pap test with ASCUS, rather than with squamous intraepithelial lesions (SILs) [3] . Current management guidelines [6] propose follow-up of ASCUS using any of the following methods: repeat cytological testing, colposcopy, or DNA testing for high-risk human papillomavirus (HPV) types. Referral for colposcopy is recommended for all HIV-infected women with ASCUS. These guidelines recommend referral for colposcopy for all women with ASCUS when high-grade SIL cannot be ruled out. ASCUS remains an incompletely described entity among HIV-uninfected women, even more so among HIV-infected women. In contrast, the increased risk of SIL among HIV-infected women has been well documented, and several groups [7, 8] have reported the increased risk of progression of SIL in this population. Fewer studies have reported on ASCUS [5] . Because there are few data on the comparative prevalence of ASCUS among HIV-infected and HIVuninfected women and on the risk of cervical intraepithelial neoplasia among HIV-infected women with ASCUS, it is difficult to know whether current management algorithms for ASCUS are optimal for HIV-infected women.
Using data from a large prospective study, we examined AS-CUS in HIV-infected women and HIV-uninfected women with similar risk profiles. We looked specifically at whether the risk or characteristics of ASCUS differ between the 2 groups and whether HIV infection alters the risk of subsequent progression to SIL among women with ASCUS.
METHODS
The HIV Epidemiology Research Study enrolled 1310 women (871 HIV-infected and 439 at-risk, HIV-uninfected women) from 4 US cities (Bronx, NY; Baltimore, MD; Providence, RI; and Detroit, MI) between April 1993 and January 1995; details of the design and enrollment procedures have been reported [9] . Institutional review boards approved the study protocol at each site and at the Centers for Disease Control and Prevention; all participants gave written, informed consent. Each site contributed approximately one-fourth of the participants. HIVinfected women without AIDS-defining conditions and HIVuninfected women were selected in such a way that about one-half reported risk related to injection drug use, and the remainder had increased risk due to sexual behavior but not injection drug use.
Pap tests were performed with a cytobrush and a wooden spatula on all women with a cervix. All Pap test results were evaluated using predefined criteria [10; an expansion of the 1988 Bethesda scoring system for cervical cytology] by a single commercial cytologic laboratory (Kyto Diagnostics, New York) [11, 12] . At 1 study site (Baltimore), cervical colposcopy was performed routinely at each study visit; at the other 3 sites, women were referred for colposcopy if they had 1 Pap test result showing SIL or 2 consecutive Pap test results showing ASCUS.
Cervical and/or vaginal secretion specimens and exfoliated cells were collected by cervicovaginal lavage and tested for HPV using PCR [9] [10] [11] .
The gynecologic exam also ascertained the presence of infectious and inflammatory conditions, discharge, visible ulcers, and condylomata. Gram stains of cervical secretion specimens were scored for the presence of polymorphonuclear leukocytes, monocytes, and bacteria. Gram stains of vaginal secretion specimens were scored for bacterial vaginosis and for the presence of yeast, sperm, RBCs, polymorphonuclear leukocytes, and monocytes. Trichomoniasis was initially defined using wet mount (at visits 1-3); culture in modified Diamond's medium was introduced for all women at visit 4. Women with symptomatic vaginal or cervical infections were either treated or referred for treatment.
HIV infection status was ascertained through ELISA and Western blotting, with assessment of immune system compromise using CD4 + cell counts, as described elsewhere [13] . HIV load was determined via a third-generation, branched DNA signal amplification assay (Chiron) with a lower quantification limit of 50 copies/mL. Antiretroviral use was ascertained by self-reporting; treatment regimens were classified as HAART, other antiretroviral therapy, or no antiretroviral therapy. Regimens not listed in published guidelines [14] were classified as HAART if they were believed to have a high likelihood of effective and sustained viral suppression. Statistical methods. Pearson's x 2 test or Fisher's exact tests were used to compare proportions, and Student's t test was used to compare means between groups. The Wilcoxon ranksum test was used for variables that were not normally distributed. The cumulative incidence of ASCUS was estimated over the course of this study using the product-limit survival estimator.
Logistic models provided estimates of overall prevalence by means of methods that compensated for within-subject correlation across multiple observations. These prevalence estimates averaged the characteristics of participants over the course of the study. Multiple logistic regression models that corrected for repeated measures were used to identify correlates of abnormal cervical cytologic findings. Initial models examined covariates one at a time and adjusted for repeated measures and 2 design variables: study site and risk category (sexual behavior or injection drug use). Factors suggesting at least a moderate ( ) association with ASCUS were included in the P ! .2 subsequent models. Interaction between HIV and other covariates was assessed and included if . Inferences were P ! .2 based on SEs estimated by robust methods using an m-dependent working correlation structure.
Cox proportional hazard models were used to calculate hazard ratios for the risk of ASCUS in women with normal Pap test results at baseline, as well as the risk of SIL in women with Pap test results showing ASCUS at baseline. Factors suggesting at least a moderate ( ) association with the outcome were P ! .2 included in the subsequent models. The multivariate model also included the design variables study site and risk category. Interaction between HIV and other covariates was assessed and included if . All calculations were performed using SAS P ! .2 software, version 8.2 (SAS Institute). 
RESULTS
We considered cervical Pap test data from the first 10 semiannual study visits (over a period of up to 4.7 years) and included results from 8185 Pap tests. Data were available for 795 HIV-infected and 404 HIV-uninfected women (N p ) with intact cervices at baseline. A median follow-up time 1199 of 4.4 years did not differ by HIV serostatus. At enrollment, HIV-infected women were more likely to be African American and were less likely to have finished high school. For the 6 months prior to enrollment, HIV-infected women were more likely to have reported always using a condom, less likely to have reported using crack, less likely to have reported having 11 male sexual partner than HIV-uninfected women. HIVinfected and HIV-uninfected women did not differ by the following factors at enrollment: risk cohort (drug use or sexual behavior), age, income, number of live births, smoking (currently), exchange of sex for drugs or money, injection drug use, and number of female sex partners (in the previous 6 months).
Characteristics of ASCUS. In general, markers of cervical inflammation observed on Pap tests or on cervical specimens collected concurrently were of similar frequency among HIVinfected and HIV-uninfected women with ASCUS (table 1) . The presence of vaginal infections that might affect Pap test ). Kaplan-Meier P ! .01 and product limit estimator method were utilized. ) (data not shown). HPV P p .43 infection, including infection caused by high-risk virus types, was more common among HIV-infected women with ASCUS than it was among HIV-uninfected women with ASCUS (P ! ). Despite this, routine colposcopy performed for all HIV-.01 infected and HIV-uninfected women at 1 site did not reveal a higher prevalence of aceto-white, punctation, mosaicism, or atypical vessels among HIV-infected women with ASCUS (data not shown). HIV-infected women with ASCUS did not have a higher prevalence of cervical intraepithelial neoplasia (table 1) .
Prevalence of and risk factors for ASCUS. Although the characteristics of ASCUS appeared not to differ according to status of HIV infection, it was more common in HIV-infected women both at the baseline visit (adjusted prevalence ratio, 1.6; 95% CI, 1.2-2.2) and during the follow-up period.
For all women, the multivariate model presented (table 2 ) contains all variables found in initial analyses to be significantly associated with the risk of ASCUS ( ). Factors examined P ! .2 in initial analyses and not found to be significantly associated with ASCUS included age, education, number of pregnancies or live births, recent sex with a woman (during the previous 6 months), condom use (during the previous 6 months), ever having exchanged sex for drugs or money, injection drug use, douching, vaginal colonization with Candida species, and bacterial vaginosis. In the final adjusted model for all women, ASCUS was associated with HIV infection; cervical ectopy present during physical exam; cervical, vaginal, and/or vulvar condyloma present during physical exam; HPV infection; race and/ or ethnicity; and Pap test result from the previous visit. The association between ASCUS and HIV infection was modified by the presence of cervical ectopy. In the multivariate model of HIV-infected women (table 2, right column), the level of ASCUS was significantly elevated in women with CD4 + cell counts !200 cells/mL (adjusted OR, 1.5; 95% CI, 1.1-2.0).
Risk of developing ASCUS. Compared with HIV-uninfected women, HIV-infected women were more likely to present with ASCUS after receiving a normal Pap test result ( figure 1) . Among the 426 HIV-infected and 275 HIV-uninfected women with normal Pap test results at enrollment, the cumulative incidence of ASCUS was 78% among the HIV-infected women and 38% among the HIV-uninfected women. In a proportional hazards model ( ), the adjusted relative hazard for ASn p 701 CUS associated with HIV infection was 1.8 (95% CI, 1.4-2.3) (table 3). HPV risk type at baseline was also associated with increased risk of progression to ASCUS. The hazard ratio of high-risk and intermediate-risk type was 3.2 (95% CI, 2.4-4.3). For low-risk and untypable HPV, the hazard ratio was 1.6 (95% CI, 1.2-2.1). Women who were culture positive for Candida species at baseline were also at risk. There was no statistical evidence of interaction between HIV infection and any other risk factor in the model. Among HIV-infected women, those with CD4 + cell counts !200 cells/mL had a hazard ratio of 1.9 (95% CI, 1.2-2.9). If ASCUS was defined as findings of ASCUS on 2 consecutive Pap tests, the cumulative incidence was reduced (27% and 7% in HIV-infected and HIV-uninfected ). Kaplan-Meier and product limit estimator P ! .01 method were utilized. women, respectively), but the associations seen did not change (data not shown).
Progression of ASCUS.
Among women with ASCUS at the enrollment visit (148 of whom were HIV infected and 48 of whom were HIV uninfected; figure 2), the cumulative incidence of SIL, according to Pap test results, was 60% among HIVinfected women and 25% among the HIV-uninfected women ( ). Among women with ASCUS at baseline who devel-P ! .01 oped SIL during the follow-up period, the median time to SIL was 12 months among HIV-infected women and 18 months among HIV-uninfected women.
Among women with ASCUS at baseline, HIV-infected women were at 2.4 times the risk of subsequently presenting with SIL, compared with HIV-uninfected women. Women with high-or intermediate-risk types of HPV were significantly more likely to later present with SIL than were women with no HPV present (table 4) .
DISCUSSION
This study found that HIV-infected women, particularly those with low CD4 + cell counts, were more likely to develop ASCUS, according to Pap test results. HIV-infected women with ASCUS were more likely to present subsequently with cytological evidence of SIL, particularly women with low CD4 + cell counts. We found that, among HIV-infected women, increased risk of ASCUS demonstrated by Pap test and increased risk of SIL were associated with infection with high-or intermediate-risk types of HPV.
A longitudinal analysis from the Women's Interagency HIV Study [15] found that, among women with normal Pap test results at baseline, a greater proportion of HIV-infected women (73.0%) than of HIV-uninfected women (42.3%) had at least 1 abnormal Pap test result during up to 5 years of follow up, and ∼30% of all women had ASCUS as a Pap test finding during this time period. In contrast to our findings, the reported prevalence of ASCUS in the Women's Interagency HIV Study did not vary significantly by status of HIV infection. By contrast, a greater proportion of HIV-infected women in the study had low-grade SIL, compared with HIV-uninfected women.
ASCUS, the most common abnormal finding by Pap test, is not reliably reproducible among cytopathologists. ASCUS has been used in the Bethesda cytological classification system to indicate abnormal squamous cells that do not meet (quantitatively or qualitatively) criteria for a diagnosis of SIL [16] . Although the majority of Pap tests demonstrating ASCUS probably reflect a benign, reactive process, they may also reflect either underlying histologic abnormalities, or they may herald the future development of a histologic abnormality. With respect to management, the current guidelines state that the following 3 algorithms are considered to be acceptable for women with ASCUS: repeat cytological examination, HPV DNA testing, and colposcopy [6] . By contrast, for women with ASCUS for whom high-grade SIL cannot be ruled out, referral for colposcopy is the only recommended option. For HIV-infected women, referral for colposcopy is recommended, regardless of immune status, despite limited evidence that addresses the appropriateness of this recommendation. Few studies have compared the incidence of ASCUS and the risk of SIL after an ASCUS Pap test among HIV-infected women.
The strengths of the present study include the large number of women who were observed; the fact that the cohorts of HIV-infected and HIV-uninfected women resembled each other with respect to HIV risk, and demographic characteristics; the long follow-up period with frequent collection of data regarding sexual behavior, and gynecological outcomes, and other medical history. This study's limitations include the fact that data were not available on the subclassification of ASCUS as ASC-US (atypical squamous cells-undetermined significance) and ASC-H (atypical squamous cells-cannot exclude high-risk squamous intraepithelial lesion [HS12]), in accordance with the most recent classification system, mainly because data collection was completed by 2000. Another limitation is the inclusion of colposcopic and histologic data for only a subset of study participants. Our finding that HIV-infected women with ASCUS are more likely than seronegative women to progress to SIL provides empirical support for the current recommendation that HIV-infected women undergo colposcopic evaluation, with histologic examination as indicated, after the first finding of ASCUS.
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